CTRI/2020/02/023250尚未招募3 期
Efficacy and Safety of Remogliflozin on Non-alcoholic fatty liver disease in diabetic patients on background Metformin therapy-A Randomized Controlled Clinical Trial
Kshirsagar Shivani Prakash0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Controlled Type 2 Diabetes Mellitus on Metformin therapy
- •Diagnosed with Non-Alcoholic Fatty liver disease
- •Fasting plasma glucose less than than 250 mg/dl
- •Willing to participate in the study and comply with it procedures by signing a written informed consent
排除标准
- •age less than 18 years and more than 75 years
- •Uncontrolled Diabetes Mellitus
- •Diabetic patients on Insulin therapy
- •Fasting plasma glucose more than 250 mg/dl
- •Viral Hepatitis
- •Autoimmune Hepatitis
- •Primary Billiary Cirrhosis
研究者
相似试验
已完成
2 期
effect of Empagliflozine on the Non-Alchoholic Fatti Liver DiseaseIRCT20210811052150N1Shahid Beheshti University of Medical Sciences140
已完成
不适用
ong-term effects of ipragliflozin on nonalcoholic fatty liver disease in patients with type 2 diabetesType 2 diabetes complicated by NAFLDJPRN-UMIN000040611Ogawa Red Cross Hospital66
已完成
不适用
Therapeutic efficacy of Pioglitazone for Non-Alcoholic Fatty Liver Desease(NAFLD) patients with impaired glucose tolerance or type 2 diabetesJPRN-UMIN000001035Tohoku University Graduate School of Medicine100
尚未招募
2 期
Effectiveness and safety of oral dapagliflozin in reducing urinary leakage of protein in children with reduced kidney function.CTRI/2022/04/042032All India Institute of Medical Sciences
已完成
不适用
Comparison of Remogliflozin with vildagliptin in the treatment of diabetesCTRI/2020/02/023120Maulana azad medical college